Etripamil (MSP-2017) 是一种短效的、L-型 钙通道 拮抗剂，能用于阵发性室上性心动过速 (PSVT) 的研究。Etripamil (MSP-2017) 通过钙离子慢通道抑制钙离子内流，从而减缓房室结传导，延长房室结不应期。
货号:ajcx39208
CAS:1593673-23-4
分子式:C27H36N2O4
分子量：452.59
溶解度:Ethanol : 120 mg/mL (265.14 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2].

[1]. Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497.
[2]. Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia.